PMID: 604623Nov 1, 1977Paper

Mechanisms of the defect in glomerular ultrafiltration associated with gentamicin administration

Kidney International
C BaylisB M Brenner

Abstract

Micropuncture studies were performed in three groups of Munich-Wistar rats: eight normal hydropenic controls (group I) and two groups (eight rats each) which were treated with gentamicin in doses of either 4 or 40 mg/kg/day for ten days (groups II and III, respectively). Following gentamicin administration, values for single nephron (SN) GFR were reduced markedly, from the control mean of 31 +/- 0.7 (SEM) nl/min to 22.4 +/- 1.5 and 20.5 +/- 0.9 for groups II and III, respectively. Declines in whole kidney GFR paralleled these falls in SNGFR. The primary cause of the reduction in SNGFR was a marked decline in glomerular capillary ultrafiltration coefficient, Kf, in both gentamicin treatment groups. None of the other determinants of glomerular ultrafiltration were significantly affected in the low dose group (group II). In the high dose group (group III), however, mean values for initial glomerular plasma flow rate and mean transglomerular hydraulic pressure difference were significantly lower than in the control group, accounting for the somewhat greater decline in SNGFR observed in group III. Electron microscopic examination of kidney tissue from rats treated with both doses of gentamicin revealed no obvious abnormalities of th...Continue Reading

References

Aug 1, 1976·The Journal of Infectious Diseases·D S GinsburgM Levin
Apr 1, 1976·Proceedings of the Society for Experimental Biology and Medicine·W M BennettG A Porter
Apr 1, 1976·The American Journal of Physiology·C BaylisB M Brenner
Feb 26, 1972·Lancet·T Kahn, R M Stein
Apr 1, 1969·The Journal of Infectious Diseases·F G FalcoG M Arcieri
Nov 1, 1972·The American Journal of Physiology·W M DeenB M Brenner
Jun 1, 1973·The Journal of Clinical Investigation·W M DeenB M Brenner
Jul 1, 1974·Proceedings of the Society for Experimental Biology and Medicine·C H HsuJ M Weller
Dec 1, 1971·The Journal of Infectious Diseases·J N WilfertC B Smith
Apr 1, 1969·The Journal of Infectious Diseases·M Finland
Jul 1, 1964·The American Journal of Physiology·C A WIEDERHIELMR F RUSHMER

❮ Previous
Next ❯

Citations

Jul 1, 1987·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·J E Bird, R C Blantz
Oct 1, 1988·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·S A Mendoza
Aug 1, 1994·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·H SmaouiJ Schaeverbeke
Jul 1, 1988·European Journal of Drug Metabolism and Pharmacokinetics·J S KakaM O Tanira
Oct 5, 1988·The American Journal of Cardiology·J P TolinsL Raij
Jun 15, 1995·Clinica Chimica Acta; International Journal of Clinical Chemistry·M WernerR Nayar
Oct 15, 1979·European Journal of Pharmacology·J BiollazL Peters-Haefeli
Jan 1, 1980·The International Journal of Biochemistry·C Baylis
Jul 1, 1988·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·J H Smith
Aug 15, 1996·Environmental Toxicology and Pharmacology·J ValdivielsoJ López-Novoa
Jul 27, 2001·European Journal of Pharmacology·E MazzonS Cuzzocrea
Nov 1, 1986·Clinics in Endocrinology and Metabolism·G C Viberti, M J Wiseman
Oct 18, 2000·Free Radical Biology & Medicine·J Pedraza-ChaverríM E Ibarra-Rubio
Jan 1, 1987·The Journal of Diabetic Complications·K Seyer-Hansen
Jun 6, 1997·Environmental Toxicology and Pharmacology·J M ValdivielsoJ M López-Novoa
May 7, 1999·Kidney International·J M López-Novoa
Jan 1, 1989·Clinical and Experimental Pharmacology & Physiology·W M Bennett
Jul 1, 1993·Antimicrobial Agents and Chemotherapy·H SmaouiJ Schaeverbeke
Sep 1, 1993·Antimicrobial Agents and Chemotherapy·O LortholaryC Carbon
Jan 1, 1980·The Journal of Clinical Investigation·P S AvasthiD Hay
May 1, 1984·The Journal of Clinical Investigation·L D DworkinB M Brenner
Aug 1, 1984·Environmental Health Perspectives·C CojocelJ B Hook
Jan 1, 2008·Future Cardiology·Janaka Karalliedde, Luigi Gnudi
Jan 1, 1979·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·J Diézi, J Biollaz
Mar 1, 2006·Expert Opinion on Drug Safety·Christina M Wyatt, Paul E Klotman
Jan 1, 1981·Clinical and Experimental Hypertension : CHE·F C LuftJ B Clark
Aug 1, 1986·The American Journal of the Medical Sciences·R E Cronin
Feb 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C Baylis
Sep 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R A Zager
Jul 1, 1982·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·H D HumesT C Knauss
Apr 1, 1984·Kidney International·M E De BroeP M Tulkens
Aug 1, 1987·Kidney International·A I WolfertD E Oken
Dec 1, 1984·Kidney International·S KobayashiA Hishida
Feb 1, 1979·Kidney International·R W Schrier
Jun 1, 1987·Kidney International·N HondaK Yonemura
Apr 1, 1980·Kidney International·P F WunderlichG Thiel
Mar 1, 1993·Kidney International·N Honda, A Hishida
Aug 1, 1985·Kidney International·P E KlotmanW E Yarger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.